RecruitingPhase 4NCT06344091

A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients

A Real World Study on Local Infiltration of Bupivacaine Liposome Injection for Acute Postoperative Pain After Pediatric Orthopedic Surgery

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Enrollment

232 participants

Start Date

May 21, 2024

Study Type

INTERVENTIONAL

Conditions

Local Analgesia Via Infiltration

Summary

The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world.

Eligibility

Min Age: 6 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bupivacaine Liposome Injection for people with local analgesia via infiltration. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBupivacaine Liposome Injection

Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)

Locations(1)

Guangzhou Women and Children's Medical Center

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06344091